Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rexahn Pharmaceuticals has initiated a Phase II clinical trial for its clinical compound Zoraxel, for the treatment of erectile dysfunction.
Subscribe to our email newsletter
Zoraxel Phase II trial is a double-blind, placebo-controlled study. This multi-center trial is expected to be completed by the end of 2008. Zoraxel is being developed as an orally administered, on-demand-use tablet.
Chang Ahn, chairman and CEO of Rexahn, said: “We are very pleased to announce the initiation of another Phase II trial. Zoraxel will prove itself a more effective, less toxic therapy for patients with erectile dysfunction.”